Putting It All Together: IWV May Be Valued at $403
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares Russell 3000 ETF (IWV) has an implied analyst target price of $403.11, indicating an 11.64% upside from its recent trading price of $361.08.
Notable Holdings with Upside: Key underlying holdings in IWV include PACS Group Inc, Inspired Entertainment Inc, and Celcuity Inc, all showing significant potential upside based on analyst targets.
Price Comparisons: PACS is currently priced at $11.73 with a target of $32.00 (172.80% upside), INSE at $8.49 with a target of $13.67 (60.97% upside), and CELC at $50.38 with a target of $69.43 (37.81% upside).
Investor Considerations: Analysts' target prices may reflect optimism but could also lead to downgrades if they are not aligned with current market conditions, prompting further investor research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 122.960
Low
94.00
Averages
106.50
High
126.00
Current: 122.960
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity Shares Drop Over 20% After Phase 3 Trial Data Release
- Trial Results Impact: Celcuity's stock plummeted over 20% on Tuesday following the release of detailed data from the VIKTORIA-1 Phase 3 trial, which, while achieving its primary endpoint of progression-free survival, revealed a Grade 5 treatment-related adverse event, raising significant safety concerns among investors.
- Adverse Event Analysis: Among the 350 patients, approximately 3% in the gedatolisib-triplet group discontinued due to treatment-related adverse events, compared to 4% in the gedatolisib-doublet group and 7% in the alpelisib plus fulvestrant group, indicating varying safety profiles across treatment combinations.
- Survival Comparison: Patients receiving the gedatolisib doublet had a median progression-free survival of 11.3 months, significantly longer than the 5.6 months for those on the alpelisib plus fulvestrant regimen, suggesting a notable therapeutic advantage that could influence future treatment decisions.
- Market Reaction and Outlook: The results are set to be presented at the ongoing ASCO meeting, and Celcuity's market outlook hinges on the FDA's decision regarding gedatolisib, expected on July 17; a favorable outcome could potentially reverse the current stock decline.
See More
Celcuity's Drug Trial Results Show Significant Efficacy
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
See More
Celcuity to Host Conference Call on VIKTORIA-1 Clinical Trial Results
- Clinical Trial Results Announcement: Celcuity plans to host a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of the VIKTORIA-1 clinical trial, which is expected to provide critical data for investors and the medical community.
- Lead Therapeutic Candidate: The company's lead therapeutic candidate, gedatolisib, acts as a kinase inhibitor of the PI3K/AKT/mTOR pathway, featuring a unique mechanism of action that may offer significant advantages in treating various solid tumors.
- Clinical Trial Progress: The VIKTORIA-1 trial evaluates the efficacy of gedatolisib in combination with fulvestrant, particularly in patients with hormone receptor-positive, HER2-negative advanced breast cancer, showing potential effectiveness against PIK3CA mutant tumors.
- Future Research Directions: Celcuity is also conducting the VIKTORIA-2 trial, assessing different treatment combinations for both endocrine-resistant and sensitive breast cancer patients, highlighting the company's ongoing innovation and growth potential in oncology treatment.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Celcuity Q1 2026 Earnings Call Insights
- FDA Review Optimism: CEO Brian Sullivan expressed optimism about the FDA's decision by July 17, although management's cautious stance on FDA interactions and refusal to answer related questions during the call may impact investor confidence.
- R&D and Financial Status: CFO Vicky Hahne reported a net loss of $52.8 million for Q1 2026, translating to a loss of $0.97 per share, with cash and short-term investments totaling $387.1 million, indicating financial pressure as the company prepares for R&D and market activities through 2027.
- Clinical Trial Expansion: Sullivan announced the expansion of the VIKTORIA-2 trial to include a study for endocrine-sensitive disease, with top-line data expected by the end of 2028, strategically enhancing the company's competitive position in breast cancer treatment.
- New Formulation Development: The company is advancing the development of a subcutaneous formulation of gedatolisib and has submitted its first patent application, indicating Celcuity's proactive approach to product diversification and market responsiveness, despite potential challenges from required FDA equivalence studies.
See More
Celcuity Q1 Earnings Beat Expectations with Strategic Financial Outlook
- Earnings Surprise: Celcuity reported a Q1 GAAP EPS of -$0.97, beating expectations by $0.09, indicating an improvement in financial performance despite ongoing losses.
- Cash Flow Pressure: The net cash used in operating activities for Q1 2026 was $55.1 million, significantly up from $35.9 million in the prior year, reflecting increased operational expenditure pressures.
- Strong Cash Reserves: At the end of Q1 2026, Celcuity had $387.1 million in cash, cash equivalents, and short-term investments, ensuring sufficient liquidity to meet operational funding needs in the coming years.
- Positive Future Outlook: The company expects to finance operations through 2027 using cash, cash equivalents, investments, and drawdowns on its debt facility, demonstrating confidence in future growth prospects.
See More
Celcuity Shares Drop Over 20% After Phase 3 Trial Data Release
- Trial Results Impact: Celcuity's stock plummeted over 20% on Tuesday following the release of detailed data from the VIKTORIA-1 Phase 3 trial, which, while achieving its primary endpoint of progression-free survival, revealed a Grade 5 treatment-related adverse event, raising significant safety concerns among investors.
- Adverse Event Analysis: Among the 350 patients, approximately 3% in the gedatolisib-triplet group discontinued due to treatment-related adverse events, compared to 4% in the gedatolisib-doublet group and 7% in the alpelisib plus fulvestrant group, indicating varying safety profiles across treatment combinations.
- Survival Comparison: Patients receiving the gedatolisib doublet had a median progression-free survival of 11.3 months, significantly longer than the 5.6 months for those on the alpelisib plus fulvestrant regimen, suggesting a notable therapeutic advantage that could influence future treatment decisions.
- Market Reaction and Outlook: The results are set to be presented at the ongoing ASCO meeting, and Celcuity's market outlook hinges on the FDA's decision regarding gedatolisib, expected on July 17; a favorable outcome could potentially reverse the current stock decline.
See More
Celcuity's Drug Trial Results Show Significant Efficacy
- Clinical Trial Results: Celcuity's experimental drug gedatolisib demonstrated a 50% reduction in the risk of disease progression or death in late-stage breast cancer patients, marking the first Phase 3 trial where this drug class clearly outperformed another, despite concerns over patient deaths.
- Survival Data: In patients with PIK3CA mutations, the median progression-free survival for the gedatolisib triplet and doublet therapies reached 11.1 months and 11.3 months respectively, significantly higher than the standard treatment's 5.6 months, indicating its potential to extend patient survival.
- Safety Analysis: While there were treatment-related deaths, the safety profile of gedatolisib remained consistent with earlier data, with serious side effects occurring in only 2.6% and 3.8% of patients in the triplet and doublet groups, respectively, compared to 7.1% in the standard treatment group.
- Market Reaction: Despite a 26% drop in stock price due to death reports, retail sentiment around CELC shifted from 'neutral' to 'extremely bullish', reflecting optimism towards the upcoming FDA decision, with CELC stock gaining approximately 687% over the past 12 months.
See More
Celcuity to Host Conference Call on VIKTORIA-1 Clinical Trial Results
- Clinical Trial Results Announcement: Celcuity plans to host a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of the VIKTORIA-1 clinical trial, which is expected to provide critical data for investors and the medical community.
- Lead Therapeutic Candidate: The company's lead therapeutic candidate, gedatolisib, acts as a kinase inhibitor of the PI3K/AKT/mTOR pathway, featuring a unique mechanism of action that may offer significant advantages in treating various solid tumors.
- Clinical Trial Progress: The VIKTORIA-1 trial evaluates the efficacy of gedatolisib in combination with fulvestrant, particularly in patients with hormone receptor-positive, HER2-negative advanced breast cancer, showing potential effectiveness against PIK3CA mutant tumors.
- Future Research Directions: Celcuity is also conducting the VIKTORIA-2 trial, assessing different treatment combinations for both endocrine-resistant and sensitive breast cancer patients, highlighting the company's ongoing innovation and growth potential in oncology treatment.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Celcuity Q1 2026 Earnings Call Insights
- FDA Review Optimism: CEO Brian Sullivan expressed optimism about the FDA's decision by July 17, although management's cautious stance on FDA interactions and refusal to answer related questions during the call may impact investor confidence.
- R&D and Financial Status: CFO Vicky Hahne reported a net loss of $52.8 million for Q1 2026, translating to a loss of $0.97 per share, with cash and short-term investments totaling $387.1 million, indicating financial pressure as the company prepares for R&D and market activities through 2027.
- Clinical Trial Expansion: Sullivan announced the expansion of the VIKTORIA-2 trial to include a study for endocrine-sensitive disease, with top-line data expected by the end of 2028, strategically enhancing the company's competitive position in breast cancer treatment.
- New Formulation Development: The company is advancing the development of a subcutaneous formulation of gedatolisib and has submitted its first patent application, indicating Celcuity's proactive approach to product diversification and market responsiveness, despite potential challenges from required FDA equivalence studies.
See More
Celcuity Q1 Earnings Beat Expectations with Strategic Financial Outlook
- Earnings Surprise: Celcuity reported a Q1 GAAP EPS of -$0.97, beating expectations by $0.09, indicating an improvement in financial performance despite ongoing losses.
- Cash Flow Pressure: The net cash used in operating activities for Q1 2026 was $55.1 million, significantly up from $35.9 million in the prior year, reflecting increased operational expenditure pressures.
- Strong Cash Reserves: At the end of Q1 2026, Celcuity had $387.1 million in cash, cash equivalents, and short-term investments, ensuring sufficient liquidity to meet operational funding needs in the coming years.
- Positive Future Outlook: The company expects to finance operations through 2027 using cash, cash equivalents, investments, and drawdowns on its debt facility, demonstrating confidence in future growth prospects.
See More
